As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
6 Analysts have issued a ReShape Lifesciences, Inc. forecast:
6 Analysts have issued a ReShape Lifesciences, Inc. forecast:
| Mar '25 |
+/-
%
|
||
| Revenue | 7.18 7.18 |
14%
14%
|
|
| Gross Profit | 4.57 4.57 |
17%
17%
|
|
| EBITDA | -6.28 -6.28 |
47%
47%
|
|
| EBIT (Operating Income) EBIT | -6.30 -6.30 |
47%
47%
|
|
| Net Profit | -3.46 -3.46 |
68%
68%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.
| Head office | United States |
| CEO | Paul Hickey |
| Employees | 18 |
| Founded | 2002 |
| Website | www.reshapelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


